ISRCTN14751416 https://doi.org/10.1186/ISRCTN14751416

Clopidose trial

Submission date 24/01/2006	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 27/01/2006	**Overall study status** Completed	[ ] Statistical analysis plan [ ] Results
Last Edited 14/02/2008	**Condition category** Circulatory System	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof François Mach

Contact details
Geneva University Hospital
Cardiology Division
24 Micheli-du-Crest
Geneva
Switzerland
1211
+41 (0)22 382 7234
francois.mach@medecine.unige.ch

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Study objectives
150 mg/day maintenance dose will increase the biological effect of clopidogrel in clopidogrel low responders

Ethics approval required
Old ethics approval format

Ethics approval(s)
This protocol has been approved by the ethics committee of the internal medicine department in November 2005

Study design
Open labelled clinical study with patients admitted for coronary angioplasty

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Cardiovascular outpatients

Interventions
After a loading dose of clopidogrel (600 mg), patients will take a standard dose of clopidogrel 75 mg once a day for 15 days.

At day 15, adenosine diphosphate (ADP) induced platelet aggregation and measurement of phosphorylated vasodilator-stimulated phosphoprotein (VASP-P) by a flow cytometric technique will be performed. If patients are clopidogrel resistant, they will receive 150 mg (2x75) once a day during the next 15 days. ADP-induced platelet aggregation and measurement of VASP-P will be performed at day 30.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)

Clopidogrel

Primary outcome measure
Biological effect of clopidogrel

Secondary outcome measures
Genetic association study

Overall study start date
01/12/2005

Completion date
30/12/2006

Eligibility

Key inclusion criteria
Cardiovascular outpatients on 75 mg/day clopidogrel

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
150

Key exclusion criteria
Anticoagulation

Date of first enrolment
01/12/2005

Date of final enrolment
30/12/2006

Locations

Countries of recruitment
Switzerland

Study participating centre
Geneva University Hospital
Geneva

Switzerland
1211

Sponsor information

Organisation
Geneva University Hospital (Switzerland)

Sponsor details
Cardiology Division
24 Micheli-du-Crest
Geneva
Switzerland
1211
+41 (0)22 382 7234
marjorie.burkhard@hcuge.ch

Sponsor type
Hospital/treatment centre

Website
http://www.cardiology-geneva.ch

ROR
https://ror.org/01m1pv723

Funder(s)

Funder type
University/education

Funder Name
University of Geneva Cardiology Foundation (GECOR)

Funder Name
Geneva University Hospital Internal Medicine Department

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration